Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease

NCT00280956 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

2000

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: natalizumab

Sponsor

Biogen

Collaborators

[object Object]